|
10:45 AM - 12:30 PM
|
1497 - Inhibition of the Plasmodium falciparum Acetyl-CoA Synthetase by multiple chemotypes disrupts protein acetylation and epigenetic regulation in blood stage parasites
Robert L. Summers1, Charisse F. Pasaje2, Manu Vanaerschot3, James M. Murithi3, Madeline R. Luth4, Justin T. Munro5, Pamela Magistrado-Coxen1, Emily F. Carpenter6, Jade Bath3, Joao P. Pisco7, Avinash S. Punekar7, Beatriz Baragaña7, Ian H. Gilbert7, Manuel Llinás8, Sabine Ottilie4, Elizabeth A. Winzeler4, Marcus C. Lee6, Jacquin C. Niles2, David A. Fidock9, Amanda K. Lukens10, Dyann F. Wirth1
1Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States, 2Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States, 3Dept. of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, United States, 4Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, United States, 5Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, United States, 6Wellcome Sanger Institute, Hinxton, United Kingdom, 7Wellcome Centre for Anti-Infectives Research, Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, United Kingdom, 8Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, United States, 9Dept. of Microbiology & Immunology & Division of Infectious Diseases, Dept. of Medicine, Columbia University Irving Medical Center, New York, NY, United States, 10Infectious Disease and Microbiome Program, Broad Institute, Cambridge, MA, United States
|
|
|
10:45 AM - 12:30 PM
|
1498 - Prodiginines as Novel Multiple Stage Active Antimalarials with Radical Cure Effect
Papireddy Kancharla1, Yuexin Li2, Brandon Pybus3, Alison Roth3, Mara Kreishman-Deitrick3, Chad Black3, Qigui Li3, Christina Nolan3, Jason Sousa3, Jane Kelly1, Kevin Reynolds1
1Portland State University, Portland, OR, United States, 2Portland VA Medical Center, Portland, OR, United States, 3Walter Reed Army Institute of Research, Silver Spring, MD, United States
|
|
|
10:45 AM - 12:30 PM
|
1500 - A first in human study to investigate the safety, pharmacokinetics and antimalarial activity of ZY-19489 in the induced blood stage Plasmodium falciparum malaria model
Bridget E. Barber1, Melissa L. Fernandez1, Hardik B. Patel2, Stephen Woolley1, Azrin N. Abd-Rahman1, Ilaria Di Resta3, Aline Fuchs3, Harilal V. Patel2, Stephan Chalon3, Parmar V. Deven2, James S. McCarthy4, Kevinkumar Kansagra2
1QIMR Berghofer Medical Research Institute, Brisbane, Australia, 2Cadila Healthcare Ltd, Ahmedabad, India, 3Medicines for Malaria Venture, Geneva, Switzerland, 4QIMR Berghofer Medical Research Institute, Brisbane, Malaysia
|
|
|
10:45 AM - 12:30 PM
|
1501 - Evaluation Of The Efficacy and Safety Of Tafenoquine Co-Administered With Dihydroartemisinin-Piperaquine For The Radical Cure (Anti-Relapse) Of Plasmodium vivax Malaria In Indonesia - INSPECTOR Study
J. Kevin Baird1, Inge Sutanto2, Amin Soebandrio3, Lenny Ekawati1, Rintis Noviyanti3, Disala Fernando4, Eve Cedar5, Alessandro Berni5, Katie Rolfe5, Sion Jones5, Stephan Duparc6, Lionel Tan5
1Eijkman Oxford Clinical Research Unit (EOCRU), Jakarta, Indonesia, 2Faculty of Medicine, University of Indonesia, Jakarta, Indonesia, 3Eijkman Institute for Molecular Biology (EIMB), Jakarta, Indonesia, 4GlaxoSmithKline, Addenbrookes Hospital, Cambridge, United Kingdom, 5GlaxoSmithKline, Stockley Park, Uxbridge, United Kingdom, 6Medicines for Malaria Venture, Geneva, Switzerland
|
|
|
10:45 AM - 12:30 PM
|
1502 - A randomized, open-label, non-comparative, multicenter study to assess the pharmacokinetics, safety, and efficacy of tafenoquine in the treatment of pediatric subjects with Plasmodium vivax malaria (TEACH study)
Ivan D. Velez1, Hien Tran2, Ana Martin3, Hema Sharma3, Vicki Rousell3, Liz Hardaker3, John Breton3, Terry Ernest4, Katie Rolfe3, Maxine Taylor4, Stephan Duparc5, Justin Green3, Navin Goyal6, Lionel Tan3
1University of Antioquia, Medellin- Antioquia, Colombia, 2Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh, Viet Nam, 3GlaxoSmithKline, London, United Kingdom, 4GlaxoSmithKline, Ware, United Kingdom, 5Medicines for Malaria Venture, Geneva, Switzerland, 6GlaxoSmithKline, Upper Providence, PA, United States
|
|